In sum, our results reveal that PP2A is a master regulator of the ISR pathway through the regulation of TFE3, ATF4 and CHOP activity, highlighting the clinical promise of PP2A-modulating molecules due to their ability to selectively target cancer cells for death while minimizing toxicity to normal tissues. Here, TFE3 is linked to cancer.